Cannabix Technologies Inc (TSE:BLO)
:BLO
Top Page
Cannabix Technologies
(BLO)
Select Model
Select Model
Rating:47Neutral
Price Target:
C$0.65
▲(8.33% Upside)
Action:ReiteratedDate:04/01/26
The score is held down primarily by weak financial performance—persistent losses, negative margins, and ongoing cash burn that implies financing dependence—despite low leverage. Technicals are a partial positive with the price trading above key moving averages and neutral momentum readings. Valuation remains a secondary drag because negative earnings make P/E less meaningful and there is no dividend support.
Positive Factors
Product focus & end-market breadth
The company targets multiple durable end-markets (workplace, law enforcement, personal testing) with breath-based cannabis and alcohol detectors. This multi-use focus supports long-term addressable market diversity and persistent demand tied to safety and enforcement needs, beyond short-term cycles.
Negative Factors
Very small TTM revenue
Trailing revenues of roughly $159k signal very limited commercial traction and scale. Such low sales make it difficult to cover fixed product development and G&A costs, increase reliance on financing, and mean commercialization risks remain large over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Product focus & end-market breadth
The company targets multiple durable end-markets (workplace, law enforcement, personal testing) with breath-based cannabis and alcohol detectors. This multi-use focus supports long-term addressable market diversity and persistent demand tied to safety and enforcement needs, beyond short-term cycles.
Read all positive factors
Cannabix Technologies (BLO) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$89.49M
Dividend YieldN/A
Average Volume (3M)36.45K
Price to Earnings (P/E)―
Beta (1Y)0.53
Revenue GrowthN/A
EPS Growth-52.41%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding122,584,110
10 Day Avg. Volume30,616
30 Day Avg. Volume36,452
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)27.07
Price to Sales (P/S)0.00
P/FCF Ratio-37.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cannabix Technologies Business Overview & Revenue Model
Company Description
Cannabix Technologies Inc., a technology company, develops marijuana breathalyzer for employers, law enforcement, governments, and public in North America. It develops tetrahydrocannabinol breath analyzers, a point of care breath testing tool for ...
How the Company Makes Money
null...
Cannabix Technologies Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 158.50K | 0.00 | 0.00 | 0.00 | 0.00 | 6.57M |
| Gross Profit | -103.03K | -168.52K | -153.24K | -126.29K | -29.22K | -25.57K |
| EBITDA | -6.09M | -4.55M | -2.96M | -2.01M | -3.11M | -9.11M |
| Net Income | -6.26M | -4.69M | -3.13M | -2.14M | -3.37M | -9.24M |
Balance Sheet | ||||||
| Total Assets | 1.83M | 3.00M | 4.70M | 6.95M | 8.76M | 10.38M |
| Cash, Cash Equivalents and Short-Term Investments | 1.26M | 2.35M | 4.26M | 6.52M | 8.45M | 10.10M |
| Total Debt | 51.31K | 158.65K | 154.58K | 132.54K | 0.00 | 0.00 |
| Total Liabilities | 256.13K | 447.71K | 248.02K | 237.17K | 120.84K | 80.78K |
| Stockholders Equity | 1.57M | 2.55M | 4.45M | 6.71M | 8.64M | 10.30M |
Cash Flow | ||||||
| Free Cash Flow | -1.88M | -1.86M | -2.11M | -2.00M | -2.13M | -1.79M |
| Operating Cash Flow | -1.87M | -1.84M | -2.08M | -1.97M | -2.13M | -1.71M |
| Investing Cash Flow | -1.12K | -17.54K | -30.96K | -28.65K | -4.59K | -121.81K |
| Financing Cash Flow | 276.00K | -58.47K | -143.53K | 10.88K | 492.50K | 3.49M |
Cannabix Technologies Technical Analysis
Positive
0.60
Price Trends
0.62
Positive
0.59
Positive
0.58
Positive
Market Momentum
0.03
Positive
54.57
Neutral
39.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BLO, the sentiment is Positive. The current price of 0.6 is below the 20-day moving average (MA) of 0.71, below the 50-day MA of 0.62, and above the 200-day MA of 0.58, indicating a bullish trend. The MACD of 0.03 indicates Positive momentum. The RSI at 54.57 is Neutral, neither overbought nor oversold. The STOCH value of 39.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BLO.
Cannabix Technologies Peers Comparison
UnderperformOutperform
Sector (51)
TSE:BLO
Cannabix Technologies
0.73
0.10
15.87%
TSE:IME
Imagin Medical
0.02
0.00
0.00%
TSE:PINK
Perimeter Medical Imaging AI
0.33
-0.07
-17.50%
TSE:VPT
VentriPoint Diagnostics
0.11
-0.04
-25.00%
Cannabix Technologies Corporate Events
Business Operations and StrategyProduct-Related Announcements
Cannabix Lands First Commercial Sale of Marijuana Breath Test to Major Construction Firm
Positive
Mar 19, 2026
Cannabix Technologies has recorded its first commercial sale of the Marijuana Breath Test (MBT) system to a major Pacific Northwest construction contractor through an authorized reseller, marking its initial penetration into the construction secto...
Business Operations and StrategyProduct-Related Announcements
Cannabix launches commercial marijuana breath test targeting recent cannabis use
Positive
Mar 16, 2026
Cannabix Technologies has begun a phased commercial rollout of its Marijuana Breath Test system, delivering units to select customers in multiple industries and preparing to scale production. The platform combines a handheld Breath Collection Unit...
Business Operations and StrategyPrivate Placements and Financing
Cannabix Technologies Raises C$700,000 in Non-Brokered Private Placement
Positive
Feb 25, 2026
Cannabix Technologies has closed a non-brokered private placement, raising C$700,000 through the issuance of 1.4 million units priced at C$0.50, each comprising one common share and a warrant exercisable at C$0.65 for 24 months with an acceleratio...
Business Operations and StrategyProduct-Related Announcements
Cannabix Marijuana Breath Test Lands Cover Spot in AlcoPro’s 2026 Catalogue
Positive
Jan 23, 2026
Cannabix Technologies’ Marijuana Breath Test (MBT) has been selected to appear on the cover of AlcoPro Inc.’s 2026 product catalogue, which is distributed to more than 85,000 businesses in the U.S. and abroad, including law enforcement...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Cannabix Wins First International BreathLogix Order, Scraps Planned Financing
Positive
Jan 2, 2026
Cannabix Technologies has secured its first international distributor order for its BreathLogix autonomous alcohol screening devices and accessories from its exclusive Australian partner, Breathalyser Sales Service Pty Ltd, covering Australia, Ne...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.